Cannabis Conundrum: Demonstrating “Accepted Medical Use” in a Restricted Research Environment October 7, 2020 Delia Deschaine Federal 0 Comments By Delia Ann Deschaine and Megan Robertson U.S. cannabis businesses operate in an increasingly complex legal and regulatory environment. Many, if not most, of those complexities stem from marijuana’s classification in Schedule I of the federal Controlled Substances Act. That… Read More→
FDA’s Draft Guidance for Clinical Research Regarding Cannabis and Cannabis Derivatives Takes a Firm Stance on the 0.3% THC Level August 25, 2020 Agustin Rodriguez Hemp Policy & Legal 0 Comments By Agustin Rodriguez and Dascher Pasco On Tuesday, July 21, 2020, the U.S. Food and Drug Administration (FDA) issued “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry.” This is the first draft guidance from the… Read More→